

FOI 2609

4th September 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Request:

I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions.

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment.

Response

Yes – The initial diagnosis and management of urothelial cancer of the bladder and upper urinary tract is undertaken by the urology service in Southern Trust. Upon confirmation of the diagnosis all patients have their care discussed in the Southern Trust urological cancer multidisciplinary meeting. This multidisciplinary team includes the local urology team who manage non muscle invasive urothelial cancer of the bladder and urothelial cancer of the upper urinary tract, and a clinical oncologist, a medical oncologist, who manage invasive / advanced and metastatic urothelial cancers of the bladder and upper urinary tract, and a urologist who is also part of the regional service providing surgical treatment for muscle invasive / advanced urothelial cancers of the bladder and upper urinary tract. All patients with muscle invasive urothelial cancer of the bladder (including locally advanced and metastatic disease), high risk non muscle invasive urothelial cancer of the bladder proceeding to surgical treatment, and advanced/metastatic upper tract urothelial cancers are also discussed at the regional specialist multidisciplinary team meeting (hosted by Belfast Trust). Patients undergoing treatment with Radiotherapy, Cystectomy/Cysotprostectomy, Systemic chemotherapy and systemic immunotherapy have their treatment undertaken in Belfast trust.

Request

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- **Atezolizumab (Tecentriq)**
- **Avelumab (Bavencio)**
- **Carboplatin single agent or in any other combination**
- **Carboplatin with Gemcitabine**
- **Carboplatin with Paclitaxel**

- **Cisplatin single agent or in any other combination**
- **Cisplatin with Gemcitabine**
- **Cisplatin with Gemcitabine + Nivolumab (Opdivo)**
- **Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Response

You may wish to redirect this part of your request to Belfast Health and Social Care Trust:

Public Liaison
Belfast HSC Trust
1st Floor, Nore Villa
Knockbracken Healthcare Park
Belfast
BT8 8BH

Email: publicliaison@belfasttrust.hscni.net

Request

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer?

Response

Patients who are eligible for clinical trials from Southern Trust are offered this option as part of the discussion of their treatment options. Currently there are no trials available in NI for non-muscle invasive bladder cancer patients. Trials for radiotherapy / systemic treatments are offered by the oncology teams in Belfast Trust.

Request

If so, can you please provide the name of each trial along with the number of patients taking part?

Response

See response to Q3

Request

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:



Southern Health and Social Care Trust

- **Atezolizumab (Tecentriq)** - 2
- **Durvalumab (Imfinzi)** - 6
- **Nivolumab (Opdivo)** - 0
- **Pembrolizumab (Keytruda)** - 0
- **Chemotherapy** - 0
- **Radiotherapy** - Treatment provided by Belfast Health and Social Care Trust*
- **Chemotherapy AND Radiotherapy** - 0

* You may wish to redirect this part of your request to Belfast Health and Social Care Trust:

Public Liaison
Belfast HSC Trust
1st Floor, Nore Villa
Knockbracken Healthcare Park
Belfast
BT8 8BH

Email: publicliaison@belfasttrust.hscni.net

Email: Foi.Team@Southerntrust.hscni.net